Clinical Trials Directory

Trials / Completed

CompletedNCT01521624

Metformin Effects on Oxidative Stress Parameters in Newly Diagnosed Type 2 Diabetes Patients

Comparing Effects of Metformin Plus Life Style Modification Compared With Life Style Modification Alone in Lowering Parameters of Oxidative Stress in Newly Diagnosed Type 2 Diabetes Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
108 (actual)
Sponsor
Tehran University of Medical Sciences · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

Oxidative stress plays a key role in the pathogenesis of diabetes complications. Chronic hyperglycemia and disturbed lipid regulation commonly seen in diabetes are the main causes of this process. Despite the critical role of oxidative stress in diabetes, most clinical trials with available antioxidants and vitamins have either failed to show any long term benefits or have produced inconsistent results (10-11). There has been growing interest in establishing the possible roles of oral hypoglycemic agents including Metformin in reduction of oxidative stress. Metformin, the most common prescribed oral medication in type 2 diabetes, lowers HbA1c around 1.5%, rarely causes hypoglycemia (compared with insulin or sulfonylureas), has relatively few contraindications, its adverse effects are generally tolerable, does not cause weight gain, is cheap, and is highly acceptable among patients. Given the long term benefits observed with metformin use, a role in modulating oxidative stress is imputable. We designed this study to evaluate the actions of metformin on oxidative stress in a group of medication-naïve newly diagnosed type 2 diabetes patients.

Conditions

Interventions

TypeNameDescription
DRUGMetforminMetformin 1000 mg Daily in two divided doses plus advice for lifestyle modification

Timeline

Start date
2010-10-01
Primary completion
2011-03-01
Completion
2011-09-01
First posted
2012-01-30
Last updated
2012-01-31

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT01521624. Inclusion in this directory is not an endorsement.